臨床泌尿器科61巻6号

2007年05月発行

綜説

前立腺癌に対するホルモン療法の現状と将来展望

著者： 鈴木啓悦¹

所属機関： ¹千葉大学大学院医学研究院泌尿器科学

ページ範囲：P.375 - P.389

要旨　前立腺はアンドロゲンの標的臓器であり，前立腺癌患者においてアンドロゲン作用の低下を中心としたホルモン療法が広く使用されている。転移病期で第一選択であるのはもちろん，早期・中期癌の補助・併用療法などとして重要な治療手段となっている。さらに，新規薬剤の開発によってホルモン療法の治療様式の組み合わせは多岐にわたってきている。さらに最近では，アンチアンドロゲン交替療法など二次ホルモン療法や間欠的ホルモン療法についても報告されてきている。本稿では，各種ホルモン療法の役割・位置付けと使用方法など現状について整理するとともに，今後のオーダーメイド医療への将来展望を踏まえて概説した。

参考文献

1）伊藤晴夫，鈴木啓悦：転移性前立腺癌に対する薬物療法．日本臨床 61（増刊：癌転移―基礎と臨床アップデート）：536-541，2003

2）鈴木啓悦，伊藤晴夫：抗アンドロゲン剤の使い方．クリニカ 29：38-43，2002

3）Huggins C and Hodges CV：Studies on prostatic cancer：Ⅰ. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. J Urol 1：293-297, 1941

4）Medical Research Council：Immediate versus deferred treatment for advanced prostatic cancer：initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Brit J Urol 79：235-246, 1997

5）Cassileth BR, Soloway MS, Vogelzang NJ, et al：Patients' choice of treatment in stage D prostate cancer. Urology 33：57-62, 1989

6）中津裕臣，赤倉功一郎，鈴木啓悦，他：LH-RHアゴニスト投与患者の通院・治療状況とこれに対する患者の満足度，要望―前立腺癌患者に対するアンケート調査より．泌尿器外科 15：119-132，2002

7）PCTCG 1995：Maximum androgen blockade in advanced prostate cancer：an overview of 22 randomised trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists' Collaborative Group. Lancet 346：265-269, 1995

8）Caubet JF, Tosteson TD, Dong EW, et al：Maximum androgen blockade in advanced prostate cancer：a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 49：71-78, 1997

9）PCTCG 2000：Maximum androgen blockade in advanced prostate cancer：an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 355：1491-1498, 2000

10）Klotz L：Combined androgen blockade in prostate cancer：meta-analyses and associated issues. BJU Int 87：806-813, 2001

11）Schellhammer P, Sharifi R, Block N, et al：A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group. Urology 45：745-752, 1995

12）Akakura K, Bruchovsky N, Goldenberg SL, et al：Effects of intermittent androgen suppression on androgen-dependent tumors：apoptosis and serum prostate-specific antigen. Cancer 71：2782-2790, 1993

13）Sato N, Gleave ME, Bruchovsky N, et al：Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J Steroid Biochem Mol Biol 58：139-146, 1996

14）Noble RL：Hormonal control of growth and progression in tumors of Nb rats and a theory of action. Cancer Res 37：82-94, 1977

15）Klotz LH, Herr HW, Morse MJ, et al：Intermittent endocrine therapy for advanced prostate cancer. Cancer 58：2546-2550, 1986

16）Sato N, Akakura K, Isaka S, et al：Intermittent androgen suppression for locally advanced and metastatic prostate cancer：preliminary report of a prospective multicenter study. Urology 64：341-345, 2004

17）鈴木啓悦：内分泌療法中止後のテストステロン値の回復．赤倉功一郎（監）：前立腺癌の間欠的内分泌療法―導入の手引きと最適なプロトコール．メジカルビュー社，東京，pp52-57，2005

18）Iversen P, Tyrrell CJ, Kaisary AV, et al：Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer：6.3 years of followup. J Urol 164：1579-1582, 2000

19）See WA, Wirth MP, McLeod DG, et al：Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer：first analysis of the early prostate cancer program. J Urol 168：429-435, 2002

20）Akaza H, Yamaguchi A, Matsuda T, et al：Superior anti-tumor efficacy of bicalutamide 80mg in combination with a luteinizing hormone-releasing hormone（LHRH）agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer：interim results of a randomized study in Japanese patients. Jpn J Clin Oncol 34：20-28, 2004

21）Gleave ME, Goldenberg SL, Chin JL, et al：Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy：biochemical and pathological effects. J Urol 166：500-506, 2001

22）Stephenson AJ, Shariat SF, Zelefsky MJ, et al：Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291：1325-1332, 2004

23）Tannock IF, de Wit R, Berry WR, et al：Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351：1502-1512, 2004

24）Petrylak DP, Tangen CM, Hussain MH, et al：Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351：1513-1520, 2004

25）Roach M Ⅲ, Lu J, Pilepich MV, et al：Predicting long-term survival, and the need for hormonal therapy：a meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys 47：617-627, 2000

26）D'Amico AV, Whittington R, Malkowicz SB, et al：Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 95：281-286, 2002

27）鈴木啓悦：前立腺癌のリスク分類―治療前PSA値，前立腺生検所見などの意義と考え方．臨床放射線〔別冊〕前立腺癌放射線治療のすべて：85-98，2006

28）D'Amico AV：Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer. Urology 60（Suppl 3A）：32-38, 2002

29）鈴木啓悦，赤倉功一郎，高波眞佐治，他：前立腺癌に対する重粒子線治療における併用内分泌療法の意義と今後の課題．泌尿器外科 19：947-950，2006

30）Akaza H, Homma Y, Usami M, et al：Efficacy of primary hormone therapy for localized or locally advanced prostate cancer：results of a 10-year follow-up. BJU Int 98：573-579, 2006

31）Kato T, Komiya A, Suzuki H, et al：The effect of androgen deprivation therapy on quality of life in Japanese men with prostate cancer. Int J Urol（inpress）

32）Scher HI, Steineck G, Kelly WK：Hormone-refractory（D3）prostate cancer：refining the concept. Urology 46：142-148, 1995

33）Kelly WK, Slovin S and Scher HI：Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance. Urol Clin North Am 24：421-431, 1997

34）鈴木啓悦：アンチアンドロゲン除去症候群とアンドロゲンレセプター．日本臨床 58（増刊：前立腺癌の診断と治療―最新の研究動向）：434-436，2000

35）Suzuki H, Sato N, Watabe Y, et al：Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol 46：759-765, 1993

36）Suzuki H, Akakura K, Komiya A, et al：Codon 877 mutation in the androgen receptor gene in advanced prostate cancer：Relation to antiandrogen withdrawal syndrome. Prostate 29：153-158, 1996

37）Suzuki H, Ueda T, Ichikawa T, et al：Androgen receptor involvement in the progression of prostate cancer. Endocrine-related Cancer 10：209-216, 2003

38）Kojima S, Suzuki H, Akakura K, et al：Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol 171：679-683, 2004

39）鈴木啓悦：アンチアンドロゲン交替療法の理論と実際．Urology View 4：24-28，2006

40）Miyake H, Hara I and Eto H：Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. BJU Int 96：791-795, 2005

41）Taplin ME and Balk SP：Androgen receptor：a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 91：483-490, 2004

42）Linja MJ, Porkka KP, Kang Z, et al：Expression of androgen receptor coregulators in prostate cancer. Clin Cancer Res 10：1032-1040, 2004

43）Fujii Y, Kawakami S, Masuda H, et al：Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy. BJU Int 97：1184-1189, 2005

44）Akakura K, Suzuki H, Komiya A, et al：Possible mechanism of dexamethasone therapy for prostate cancer：Suppression of circulating levels of interleukin-6. Prostate 56：106-109, 2003

45）鈴木啓悦：内分泌疾患UPDATE：前立腺癌のホルモン依存性―依存性喪失（再燃）機構を含めて．医学のあゆみ 213：527-532，2005

46）D'Amico AV, Chen MH, Cox MC, et al：Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer. Urology 66：571-576, 2005

47）鈴木啓悦：各種ノモグラムの応用．伊藤晴夫（監）：改訂版・前立腺癌のすべて．メジカルビュー社，東京，pp136-139，2004

48）Stephenson AJ and Kattan MW：Nomograms for prostate cancer. BJU Int 98：39-46, 2006

49）Smaletz O, Scher HI, Small EJ, et al：Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 20：3972-3982, 2002

50）Imamoto T, Suzuki H, Akakura K, et al：Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer. Endocr J 48：573-578, 2001

51）Chodak GW, Vogelzang NJ, Caplan RJ, et al：Independent prognostic factors in patients with metastatic（stage D2）prostate cancer. The Zoladex Study Group. JAMA 265：618-621, 1991

52）Imamoto T, Suzuki H, Fukasawa S, et al：Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy. Eur Urol 47：308-312, 2005

53）Massengill JC, Sun L, Moul JW, et al：Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 169：1670-1675, 2003

54）Nakashima J, Tachibana M, Horiguchi Y, et al：Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 6：2702-2706, 2000

55）Ueda T, Sadar MD, Suzuki H, et al：Interleukin-4 in patients with prostate cancer. Anticancer Res 25：4595-4598, 2005

56）Ueda T, Bruchovsky N and Sadar MD：Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 277：6076-6085, 2002

57）舛森直哉：前立腺における神経内分泌細胞．臨泌 60：439-451，2006

58）Isshiki S, Akakura K, Komiya A, et al：Chromogranin A concentration as a serum marker to predict prognosis after endocrine therapy in prostate cancer. J Urol 167：512-515, 2002

59）Kamiya N, Akakura K, Suzuki H, et al：Pretreatment serum level of Neuro Specific Enolase（NSE）as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy. Eur Urol 44：309-314, 2003

60）Sasaki T, Komiya A, Suzuki H, et al：Changes in chromogranin A serum levels during endocrine therapy in metastatic prostate cancer patients. Eur Urol 48：224-230, 2005

61）鈴木啓悦：前立腺癌におけるバイオマーカー（遺伝子診断を含めて）の新展開．日本臨床 63：351-359，2005

62）Tsuchiya N, Wang L, Suzuki H, et al：Impact of IGF-Ⅰ and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer. J Clin Oncol 24：1982-1989, 2006

63）Shimbo M, Suzuki H, Kamiya N, et al：CAG polymorphic repeat length in androgen receptor gene combined with pretreatment serum testosterone level as prognostic factor in patients with metastatic prostate cancer. Eur Urol 47：557-563, 2005

64）Saad F, Gleason DM, Murray R, et al：A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94：1458-1468, 2002

65）原　勲，筧　善行，鈴木啓悦，他：第8章　緩和医療．日本泌尿器科学会（編）：前立腺癌診療ガイドライン．金原出版，東京，pp225-233，2006